« Back
Immatics Presenting at CHI’s Annual Cell Therapy CMC and Manufacturing Conference – Characterizing and Commercializing Cell-Based Therapies
Jul 21 - Jul 23, 2020
Stay virtually connected to the Bioprocessing Community at CHI’s Annual Bioprocessing Summit Europe
E-interact with us on July 21-23 at Cambridge Healthtech Institute’s (CHI) Annual Cell Therapy CMC and Manufacturing Conference and discuss the latest developments and trends in cell culture, cell line, protein expression, recovery, purification, cell and gene therapy manufacturing, as well as analytical characterization, formulation and aggregates!
Virtually join Ali Mohamed for stream #3 Cell and Gene Therapy’s Q&A panel discussion on scale-up and automation and for insights into cell-based manufacturing at Immatics:
Tuesday, July 21, 1.25pm CEST (7.25am EST)
Stream #3: Cell and Gene Therapy ǀ Scale-Up and Automation
Panel Discussion: Q&A with Speakers – Scale-Up and Automation stream
Moderator: Ali Mohamed, VP CMC Immatics
Panelists: Robert Allen, Principal Dark Horse Consulting (talk: The Long Road to Affordability: A COG Analysis for a CAR-T Process)
Rhys Macown, Lead Scientist Industrialisation, Cell & Gene Therapy Catapult (talk: Closed, Automated and Controlled Processing for Cell-Based Therapies)
Tuesday, July 21, 2pm CET (8am EST)
Stream #3: Cell and Gene Therapy ǀ Scale-Up and Automation
Talk Ali Mohamed: Manufacturing Platforms for Endogenous, Autologous, and Allogeneic TCR T Cell Therapies for Solid Cancers
Immatics utilizes target discovery platform, XPRESIDENT®, which identifies tumor targets and screens cognate TCRs for off-target toxicities. TCRs against these tumor targets are used in various Immatics’ adoptive cell therapy programs that include endogenous autologous, engineered autologous, and engineered allogeneic product candidates for various cancer indications. Extensive process development led to the manufacturing approaches for the various product platforms and exemplary manufacturing and/or clinical data from various trials will be presented.
Tuesday, July 21, 2.40pm CET (8.40am EST)
Stream #3: Cell and Gene Therapy ǀ Scale-Up and Automation
Panel Discussion: Q&A with Speakers – Scale-Up and Automation stream
Moderator: Robert Allen, Principal Dark Horse Consulting
Panelists: Ali Mohamed, VP CMC Immatics (talk: Manufacturing Platforms for Endogenous, Autologous, and Allogeneic TCR T Cell Therapies for Solid Cancers)
Frouad Atouf, VP Global Biologics USP (talk: Advanced Therapies: Challenges and Opportunities for Standardization)
Tuesday, July 21, 2.55pm CET (8.55am EST)
Stream #3: Cell and Gene Therapy ǀ Scale-Up and Automation
Virtual Exhibition Ali Mohamed: Manufacturing and Controlling Cell-based Manufacturing
- Scaling up cell-based therapies
- Raw material, quality control, monitoring
- Vein to vein times, closed manufacturing
We are looking forward to e-meeting you!
Learn more about CHI’s Annual Bioprocessing Summit Europe & CHI’s Annual Cell Therapy CMC and Manufacturing Conference here.